TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15291652

Group type: EXPERIMENTAL
Intervention: Antipsychotic medications
Number of subjects: 20
Study: 11718088

Group type: EXPERIMENTAL
Intervention: Double autologous hematopoietic stem cell transplantation (DAHSCT)
Number of subjects: 13
Study: 9146599

Group type: EXPERIMENTAL
Intervention: Papaverine plus phentolamine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 60
Study: 7515652

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 1138

Group type: EXPERIMENTAL
Intervention: ProMACE-CytaBOM
Number of subjects: 1138

Group type: EXPERIMENTAL
Intervention: m-BACOD
Number of subjects: 1138

Group type: EXPERIMENTAL
Intervention: MACOP-B
Number of subjects: 1138

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 1138
Study: 3079054

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 69

Group type: COMPARATOR
Intervention: No Prednisone
Number of subjects: 69
Study: 28678568

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/d)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 27466236

Group type: EXPERIMENTAL
Intervention: High-dose ibuprofen (2400 mg/day for 4 or 12 weeks)
Number of subjects: 12
Study: 24916786

Group type: EXPERIMENTAL
Intervention: Shared decision-making intervention with continuing medical education (CME) and patient activation tools.
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Follow-up study phase.
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Patient activation intervention.
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Intervention by study phase interaction.
Number of subjects: 355

Group type: COMPARATOR
Intervention: Comparison group with only CME.
Number of subjects: 355
Study: 23819220

Group type: EXPERIMENTAL
Intervention: Sancai Needling - EA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ashi-point - EA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine EA treatment
Number of subjects: 60
Study: 20948493

Group type: EXPERIMENTAL
Intervention: Non-invasive biofeedback electrical stimulation
Number of subjects: 30
Study: 18258367

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16361594

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 12798752

Group type: EXPERIMENTAL
Intervention: Hepatic artery occlusion (HAO) followed by intraportal 5‐fluorouracil (5‐Fu) infusion (1000 mg/m(2) for 5 days every sixth week)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Intra-arterial 5‐Fu infusion + Leucovorin (100 mg i.v. for 2 days every second week) (HAI)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Comparison of survival between HAO and HAI groups
Number of subjects: 39

Group type: COMPARATOR
Intervention: Time to progression
Number of subjects: 39
Study: 10724201

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials with adequate randomization and reporting
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Simple randomization
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Randomized trials
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Trials reporting sample size and statistical power considerations
Number of subjects: 73
Study: 8865594

Group type: EXPERIMENTAL
Intervention: 0.83 N keyboard
Number of subjects: 6

Group type: COMPARATOR
Intervention: 0.28 N keyboard
Number of subjects: 6
Study: 1735268

Group type: EXPERIMENTAL
Intervention: Incentive spirometry at 30 degrees recumbency angle
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Incentive spirometry at 60 degrees recumbency angle
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study: 3928215

Group type: EXPERIMENTAL
Intervention: tocainide hydrochloride (200-600 mg daily)
Number of subjects: 32
Study: 28580795

Group type: EXPERIMENTAL
Intervention: Self-directed nutrition intervention
Number of subjects: 321

Group type: COMPARATOR
Intervention: Self-directed exercise intervention
Number of subjects: 321
Study: 26983011

Group type: EXPERIMENTAL
Intervention: Salivary alpha-amylase (sAA)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Free cortisol
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Secretory IgA (sIgA)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Correlation between cortisol and sIgA
Number of subjects: 47

Group type: COMPARATOR
Intervention: Comparison to healthy individuals
Number of subjects: 47
Study: 25464675

Group type: EXPERIMENTAL
Intervention: Lean body mass index
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Fat mass index
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Fat free mass index
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Body fat
Number of subjects: 733
Study: 22422577

Group type: EXPERIMENTAL
Intervention: MitraClip intervention
Number of subjects: 30
Study: 20167156

Group type: EXPERIMENTAL
Intervention: Chronic disease management program focused on blood pressure reduction
Number of subjects: 60
Study: 17768053

Group type: EXPERIMENTAL
Intervention: Fenretinide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: E2
Number of subjects: 10

Group type: COMPARATOR
Intervention: CEE
Number of subjects: 10
Study: 19298039

Group type: EXPERIMENTAL
Intervention: Acetabular center axis (ACA) registration technique
Number of subjects: 34

Group type: COMPARATOR
Intervention: Anterior pelvic plane (APP) registration technique
Number of subjects: 34
Study: 15043640

Group type: COMPARATOR
Intervention: Independent self-construal priming
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interdependent self-construal priming
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic self-construal
Number of subjects: 0
Study: 11736967

Group type: EXPERIMENTAL
Intervention: Patient-controlled postoperative oral feeding (PC group)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Fixed regimen postoperative oral feeding (FR group)
Number of subjects: 105
Study: 9237935

Group type: EXPERIMENTAL
Intervention: GLA supplementation at doses of 3.0 g/d and 6.0 g/d
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: GLA supplementation at doses of 3.0 g/d
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (typical Western diets)
Number of subjects: 29
Study: 8516499

Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD)
Number of subjects: 811

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 811
Study: 2964992

Group type: EXPERIMENTAL
Intervention: Full dose HRP112 (25mg DMPA plus 5mg estradiol cypionate)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Half dose HRP112 (12.5mg DMPA plus 2.5mg estradiol cypionate)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Full dose DMPA (25mg)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Half dose DMPA (12.5mg)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Estrogen-progestogen combination preparations
Number of subjects: 88

Group type: COMPARATOR
Intervention: DMPA alone
Number of subjects: 88
Study: 29557731

Group type: EXPERIMENTAL
Intervention: NeuroPage service (reminder messages to mobile phones)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control condition (non-memory texts)
Number of subjects: 38
Study: 30791701

Group type: EXPERIMENTAL
Intervention: Neutral photos
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Group selfies
Number of subjects: 110
Study: 28541533

Group type: EXPERIMENTAL
Intervention: M‐Marsh model
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Schnider model
Number of subjects: 30
Study: 25869509

Group type: EXPERIMENTAL
Intervention: High flavanol dark chocolate (HFDC; 1064mg flavanols/day for 6 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low flavanol dark chocolate (LFDC; 88mg flavanols/day for 6 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High flavanol dark chocolate (HFDC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High flavanol dark chocolate (HFDC) and Low flavanol dark chocolate (LFDC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theobromine (pre-incubation of platelets)
Number of subjects: 0
Study: 22901564

Group type: EXPERIMENTAL
Intervention: Point-of-care test for comprehensive metabolic panel (n=5,154)
Number of subjects: 10244

Group type: COMPARATOR
Intervention: Central laboratory testing (n=5,090)
Number of subjects: 10244
Study: 21335691

Group type: EXPERIMENTAL
Intervention: Email notifications for sentinel health events sent to care managers
Number of subjects: 13454

Group type: COMPARATOR
Intervention: Control group (no email notifications)
Number of subjects: 13454
Study: 19245538

Group type: EXPERIMENTAL
Intervention: Poly-l-lactic acid (PLA) injections administered every 2 weeks from week 0 (immediate group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Poly-l-lactic acid (PLA) injections administered every 2 weeks from week 24 (deferred group)
Number of subjects: 100
Study: 16308413

Group type: EXPERIMENTAL
Intervention: Exercise training for 6 months
Number of subjects: 104

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 104
Study: 14760045

Group type: EXPERIMENTAL
Intervention: Instant photography included in referral letters
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (no instant photography)
Number of subjects: 136
Study: 11501509

Group type: EXPERIMENTAL
Intervention: Calcitriol 3 microg g(‐1) ointment applied twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcitriol combined with UVB phototherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcitriol combined with betamethasone valerate (each applied separately, once daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcitriol 3 microg g(‐1) ointment
Number of subjects: 0
Study: 9532517

Group type: EXPERIMENTAL
Intervention: Irbesartan 75 mg once a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg once a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irbesartan 75 mg twice a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8300487

Group type: EXPERIMENTAL
Intervention: Aerosolised nifedipine 5 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aerosolised verapamil 5 mg
Number of subjects: 20
Study: 3572619

Group type: EXPERIMENTAL
Intervention: Soy protein isolate‐based formula (Isomil with Iron)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cow milk protein‐based formula (Similac with Iron)
Number of subjects: 36
Study: 31870942

Group type: EXPERIMENTAL
Intervention: Cortisol (1 mg intravenously)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 30200398

Group type: EXPERIMENTAL
Intervention: 2 g of dark chocolate containing 70% cocoa
Number of subjects: 84

Group type: COMPARATOR
Intervention: 2 g of milk chocolate
Number of subjects: 84
Study: 27555754

Group type: EXPERIMENTAL
Intervention: Exercise program (four-stage exercise program)
Number of subjects: 46
Study: 24602210

Group type: EXPERIMENTAL
Intervention: Theory of Planned Behaviour (TPB) based online intervention
Number of subjects: 420

Group type: COMPARATOR
Intervention: Information only
Number of subjects: 420

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 420
Study: 23338255

Group type: EXPERIMENTAL
Intervention: 0.1% CPC with positive‐pressure irrigation (PPI, Conventional, NaviTip(®))
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.2% CPC with positive‐pressure irrigation (PPI)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl with positive‐pressure irrigation (PPI)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl with negative‐pressure irrigation system (NPI, EndoVac(®))
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CPC
Number of subjects: 40

Group type: COMPARATOR
Intervention: Positive control
Number of subjects: 40

Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 40
Study: 20513644

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (age-matched children with tension type headache)
Number of subjects: 20
Study: 18981372

Group type: EXPERIMENTAL
Intervention: Higher CAG repeat number in patients with HD
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: R6/2 mouse model with larger CAG repeat length
Number of subjects: 517
Study: 15979994

Group type: EXPERIMENTAL
Intervention: 0.2 mg Triptorelin (GnRH agonist)
Number of subjects: 106

Group type: COMPARATOR
Intervention: 10 000 IU urinary HCG
Number of subjects: 106
Study: 11227971

Group type: EXPERIMENTAL
Intervention: 50%/50% tilt biphasic waveform
Number of subjects: 60

Group type: COMPARATOR
Intervention: 65%/65% tilt biphasic waveform
Number of subjects: 60
Study: 9688055

Group type: EXPERIMENTAL
Intervention: Moderately stressed capsules
Number of subjects: 9

Group type: COMPARATOR
Intervention: Unstressed capsules
Number of subjects: 9
Study: 7748864

Group type: EXPERIMENTAL
Intervention: Study group (Strip mutans test for caries risk assessment)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 528
Study: 3176071

Group type: EXPERIMENTAL
Intervention: Acetone at 250 ppm
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Methyl ethyl ketone (MEK) at 200 ppm
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Acetone at 125 ppm with MEK at 100 ppm
Number of subjects: 137

Group type: COMPARATOR
Intervention: Ethanol (95%, 0.84 ml/kg) as positive control
Number of subjects: 137

Group type: COMPARATOR
Intervention: Chemical-placebo
Number of subjects: 137
Study: 31493942

Group type: EXPERIMENTAL
Intervention: RIMO intervention
Number of subjects: 33

Group type: COMPARATOR
Intervention: Passive referral control
Number of subjects: 33
Study: 30184254

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% (2.5 ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% (5.0 ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% (10 ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% (15 ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% (20 ml)
Number of subjects: 60
Study: 26032281

Group type: EXPERIMENTAL
Intervention: Yohimbine (α2-adrenoceptor antagonist)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 24385236

Group type: EXPERIMENTAL
Intervention: ETC-1002 80 mg QD for 2 weeks followed by 120 mg QD for 2 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ETC-1002
Number of subjects: 60
Study: 22197589

Group type: EXPERIMENTAL
Intervention: Markers in the polyethylene as reference segment
Number of subjects: 31

Group type: COMPARATOR
Intervention: Markers in the periacetabular bone as reference segment
Number of subjects: 31
Study: 20411425

Group type: EXPERIMENTAL
Intervention: Low-air insufflation limited to the rectum and sigmoid colon (group C)
Number of subjects: 250
Study: 18824288

Group type: EXPERIMENTAL
Intervention: Ferumoxytol (IV injection of 17 mL over 17 seconds)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Saline placebo (IV injection of 17 mL over 17 seconds)
Number of subjects: 750
Study: 16015004

Group type: EXPERIMENTAL
Intervention: Quinapril (Q)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Amlodipine (A)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Quinapril and Amlodipine (Q&A)
Number of subjects: 73
Study: 12359651

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (100 micro g, twice daily)
Number of subjects: 61
Study: 11063439

Group type: EXPERIMENTAL
Intervention: Fructose diet (17% of energy as fructose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Glucose diet (nearly devoid of fructose)
Number of subjects: 24
Study: 8836653

Group type: EXPERIMENTAL
Intervention: Cyclosporin therapy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 33
Study: 1467074

Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg i.m. 12-hourly for 2 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6584028

Group type: EXPERIMENTAL
Intervention: 3 mg prostaglandin E2 vaginal pessaries
Number of subjects: 202

Group type: COMPARATOR
Intervention: Oxytocin alone
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Oxytocin (after prostaglandin)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2
Number of subjects: 202
Study: 30710389

Group type: EXPERIMENTAL
Intervention: DBBM
Number of subjects: 66

Group type: COMPARATOR
Intervention: DBBM-C
Number of subjects: 66
Study: 29508715

Group type: EXPERIMENTAL
Intervention: 10 mg of montelukast for 2 weeks followed by 10 mg of montelukast for 2 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 20 mg of prednisolone for 2 weeks followed by 10 mg of montelukast for 2 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: 10 mg of montelukast for 2 weeks
Number of subjects: 50
Study: 27245789

Group type: EXPERIMENTAL
Intervention: Web-based, computer-tailored intervention with personalized feedback and tips
Number of subjects: 213

Group type: COMPARATOR
Intervention: Generic web-based advice with tips
Number of subjects: 213

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 213
Study: 24389416

Group type: EXPERIMENTAL
Intervention: zoledronate 5mg i.v. annually
Number of subjects: 60

Group type: COMPARATOR
Intervention: ibandronate 3mg i.v. every 3 months
Number of subjects: 60
Study: 22878803

Group type: EXPERIMENTAL
Intervention: losartan 50 mg/hydrochlorothiazide 12.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: amlodipine 5 mg
Number of subjects: 0
Study: 20230461

Group type: EXPERIMENTAL
Intervention: Moxonidine 0.4 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 17510755

Group type: EXPERIMENTAL
Intervention: SEDS salbutamol sulfate (three batches)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Asmasal inhaler (micronized drug)
Number of subjects: 23
Study: 15653940

Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 1801

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1801
Study: 11208637

Group type: EXPERIMENTAL
Intervention: Bilevel ventilatory support (BVS)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Low-flow oxygen (LFO2)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Room air (RA)
Number of subjects: 13
Study: 8996294

Group type: EXPERIMENTAL
Intervention: Titrated oral ramipril (n = 20)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional therapy (control, n = 15)
Number of subjects: 35
Study: 8488685

Group type: EXPERIMENTAL
Intervention: Theospirex retard 300 mg (single evening dose)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Reference preparation (400 mg, single evening dose)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both preparations (Theospirex retard and reference preparation)
Number of subjects: 19
Study: 2963686

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early angiography
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 2575875

Group type: EXPERIMENTAL
Intervention: Sufentanil-pancuronium
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sufentanil-vecuronium
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 30088199

Group type: EXPERIMENTAL
Intervention: Alcohol beverages
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Placebo beverages
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control beverages
Number of subjects: 121
Study: 28272718

Group type: EXPERIMENTAL
Intervention: BNP (biodegradable nasopore)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Merocel (Merocel Hemox 10 cm)
Number of subjects: 72
Study: 25439606

Group type: EXPERIMENTAL
Intervention: AGV
Number of subjects: 276

Group type: COMPARATOR
Intervention: BGI
Number of subjects: 276
Study: 23245456

Group type: EXPERIMENTAL
Intervention: Team and leaders-directed strategy
Number of subjects: 67

Group type: COMPARATOR
Intervention: State-of-the-art strategy
Number of subjects: 67
Study: 21321419

Group type: EXPERIMENTAL
Intervention: Adefovir
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 30
Study: 19301059

Group type: EXPERIMENTAL
Intervention: Pantoprazole (80 mg i.v. bolus followed by 8 mg/h for 1 h)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 18
Study: 16740419

Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate
Number of subjects: 0
Study: 15578473

Group type: EXPERIMENTAL
Intervention: target-controlled propofol (1-8 microg/mL plasma target concentration)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: sevoflurane (1%-4% end-tidal concentration)
Number of subjects: 360

Group type: COMPARATOR
Intervention: isoflurane (0.5%-2% end-tidal concentration)
Number of subjects: 360
Study: 11382369

Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (2g/day orally) for 6 months
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine
Number of subjects: 155
Study: 8993260

Group type: EXPERIMENTAL
Intervention: pH-stat acid-base management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: alpha-stat acid-base management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relative changes in CBF and VMCA
Number of subjects: 0
Study: 8357499

Group type: EXPERIMENTAL
Intervention: Jogging
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dieting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise without dieting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prudent diet (low fat, low cholesterol) + exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise addition to dietary change
Number of subjects: 0
Study: 2442541

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179